5328722025-04-012025-06-305328722025-04-012025-06-30in-capmkt:OtherExpenses1Member5328722025-04-012025-06-30in-capmkt:OtherExpenses2Member5328722025-04-012025-06-30in-capmkt:OtherExpenses3Member5328722025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15328722025-04-012025-06-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532872SPARCNAINE232I01014Sun Pharma Advanced Research Company LimitedMain BoardEquity2025-04-012026-03-312025-08-042025-07-28INRLakhsQuarterlyFirst quarterSingle segmentPharmaceutical Research and Development2025-08-0411:30:002025-08-0413:45:00Declaration of unmodified opinion2025-04-012025-06-30UnauditedConsolidated964000009140000018780000051300000003132000006190000026800000252700000705900000-5181000000-51810000006000006000000-5187000000000-518700000-600000-519300000-51930000003245000001-1.6-1.600-1.6-1.61. These unaudited consolidated financial results relate to Sun Pharma Advanced Research Company Limited the Company and its Wholly Owned Subsidiary together the Group and are prepared by applying Ind AS 110 Consolidated Financial Statements. <BR> <BR> 2.The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 4 2025. <BR> <BR> 3.The above unaudited consolidated financial results have been prepared in accordance with the Companies Indian Accounting Standards Rules, 2015 Ind AS as amended prescribed under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder. <BR> <BR> 4.The Group has incurred cash losses in past quarters and in the current quarter. The Group has a support letter from its promoter group entity basis which its status as Going Concern continues. <BR> <BR> 5.The Group has only one reportable business segment namely Pharmaceutical Research and Development. <BR> <BR> 6.The figures for the quarter ended March 31 2025 represent the derived figures between the audited figures in respect of the full financial year ended March 31 2025 and the unaudited published year to date figures upto December 31 2024 being the date of the end of third quarter of the financial year which were subjected to a limited review by the statutory auditor of the Group.Clinical trial expenses / products development expense55400000Professional charges100700000Other expenses96600000a. Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)-600000-60000000-600000UnauditedtrueSRBC AND CO LLPtrue2026-02-28